Primary results of matched cohort analyses on acute hospital mortality versus PROWESS at 28 days

PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.<p><b>Copyright information:</b></p><p>Taken from "Drotrecogin alfa (activated): real-life use and outcomes for the UK"</p><p>http://ccforum.com/content/12/2/R58</p><p>Critical Care 2008;12(2):R58-R58.</p><p>Published online 22 Apr 2008</p><p>PMCID:PMC2447613.</p><p>